Lipocine Inc

LPCN

Company Profile

  • Business description

    Lipocine Inc is a clinical-stage biopharmaceutical company that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates, or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy (TRT). It also has other products in the pipeline, such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.

  • Contact

    675 Arapeen Drive
    Suite 202
    Salt Lake CityUT84108
    USA

    T: +1 801 994-7383

    E: [email protected]

    https://www.lipocine.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    14

Stocks News & Analysis

stocks

ASX listed bank overvalued despite strong earnings

Profit beats drive shares higher for Australia’s largest asset manager.
stocks

After earnings, is Amazon a buy, a sell, or fairly valued?

After the launch of Amazon Supply Chain Services, here’s what we think of the stock.
stocks

ASX retail share expected to recover despite choppy conditions

Weakening consumer demand a temporary headwind for ASX retailer.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,942.4014.500.16%
CAC 408,056.3856.19-0.69%
DAX 4024,350.2811.650.05%
Dow JONES (US)49,724.40115.240.23%
FTSE 10010,269.4336.360.36%
HKSE26,406.8413.130.05%
NASDAQ26,328.3181.230.31%
Nikkei 22562,417.88295.77-0.47%
NZX 50 Index13,210.4835.350.27%
S&P 5007,424.9926.060.35%
S&P/ASX 2008,701.8011.500.13%
SSE Composite Index4,225.0245.071.08%

Market Movers